Adaptive responses of low-grade ovarian cancer cell lines to MEK inhibitor

被引：0
|
作者：
Wong, Kwong-Kwok [1 ]
Tsang, Yvonne T. [1 ]
Chen, Michelle [1 ]
Kun, Eucharist H. [1 ]
Gershenson, David M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2019年 / 18卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-19-C089
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C089
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines
    Fernandez, Marta Llaurado
    DiMattia, Gabriel E.
    Dawson, Amy
    Bamford, Sylvia
    Anderson, Shawn
    Hennessy, Bryan T.
    Anglesio, Michael S.
    Shepherd, Trevor G.
    Salamanca, Clara
    Hoenisch, Josh
    Tinker, Anna
    Huntsman, David G.
    Carey, Mark S.
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (10): : 2235 - 2251
  • [2] CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines.
    Hoenisch, Joshua
    Kim, Hannah
    Dawson, Amy
    Lam, Nicole
    Cheasley, Dane A.
    Gorringe, Kylie
    Campbell, Ian
    Huntsman, David G.
    DiMattia, Gabriel
    Kobel, Martin
    Fernandez, Marta Llaurado
    Carey, Mark S.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 91 - 91
  • [3] PREDICTORS OF MEK INHIBITOR RESPONSE IN LOW GRADE SEROUS OVARIAN CANCER CELL LINES.
    Carey, M.
    Dawson, A.
    Hoenisch, J.
    Kim, H.
    Chui, K.
    Bamford, S.
    Salamanca, C.
    Cremona, M.
    Anderson, S.
    Volik, S.
    Le Bihan, S.
    Collins, C.
    Morin, G.
    Huntsman, D.
    DiMattia, G.
    Hennessy, B.
    Llaurado-Fernandez, M.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 135 - 135
  • [4] Treatment of Recurrent Low-grade Serous Ovarian Cancer With MEK Inhibitors
    Kulkarni, Anjali
    Cooke, Carly
    Fazelzad, Rouhi
    Fung-Kee-Fung, Michael
    May, Taymaa
    Zigras, Tiffany
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2024, 47 (01): : 11 - 16
  • [5] Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
    Marta Llaurado Fernandez
    Amy Dawson
    Joshua Hoenisch
    Hannah Kim
    Sylvia Bamford
    Clara Salamanca
    Gabriel DiMattia
    Trevor Shepherd
    Mattia Cremona
    Bryan Hennessy
    Shawn Anderson
    Stanislav Volik
    Colin C. Collins
    David G. Huntsman
    Mark S. Carey
    Cancer Cell International, 19
  • [6] MEK inhibition for low-grade serous ovarian cancer: are we there yet?
    Scaranti, Mariana
    Mathias-Machado, Maria Cecilia
    Guo, Christina
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 (01) : 155 - 156
  • [7] Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target
    Fernandez, Marta Llaurado
    Dawson, Amy
    Hoenisch, Joshua
    Kim, Hannah
    Bamford, Sylvia
    Salamanca, Clara
    DiMattia, Gabriel
    Shepherd, Trevor
    Cremona, Mattia
    Hennessy, Bryan
    Anderson, Shawn
    Volik, Stanislav
    Collins, Colin C.
    Huntsman, David G.
    Carey, Mark S.
    CANCER CELL INTERNATIONAL, 2019, 19 (1)
  • [8] Mutations in low-grade serous ovarian cancer and response to BRAF and MEK inhibitors
    Moujaber, Tania
    Etemadmoghadam, Dariush
    Mapagu, Cristina
    Kennedy, Catherine
    Chiew, Yoke-Eng
    Kan, Casina
    Nevins, Nikilyn
    Srirangan, Sivatharsny
    Fereday, Sian
    Traficante, Nadia
    Bowtell, David
    Balleine, Rosemary
    Harnett, Paul
    deFazio, Anna
    CANCER RESEARCH, 2018, 78 (13)
  • [9] High throughput drug screening to decipher the mechanisms of trametinib adaptive resistance in low-grade serous ovarian cancer cell lines
    Wong, Kwong-Kwok
    Ng, Chun Wai
    Tsang, Yvonne
    Gershenson, David M.
    CANCER RESEARCH, 2024, 84 (05)
  • [10] MEK Inhibitors for the Treatment of Low-Grade Serous Ovarian Cancer: Expanding Therapeutic Options for a Rare Ovarian Cancer Subtype
    Gershenson, David M.
    Gourley, Charlie
    Paul, James
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) : 3731 - +
12345